Mariner LLC Has $2.28 Million Holdings in argenx SE (NASDAQ:ARGX)

Mariner LLC grew its stake in argenx SE (NASDAQ:ARGX - Free Report) by 15.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,711 shares of the company's stock after acquiring an additional 509 shares during the period. Mariner LLC's holdings in argenx were worth $2,283,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Steward Partners Investment Advisory LLC lifted its position in argenx by 5.6% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 380 shares of the company's stock worth $234,000 after acquiring an additional 20 shares during the period. SG Americas Securities LLC raised its holdings in shares of argenx by 6.2% during the fourth quarter. SG Americas Securities LLC now owns 358 shares of the company's stock valued at $220,000 after acquiring an additional 21 shares during the last quarter. Farther Finance Advisors LLC raised its position in shares of argenx by 38.2% in the fourth quarter. Farther Finance Advisors LLC now owns 76 shares of the company's stock valued at $47,000 after buying an additional 21 shares during the last quarter. Dynasty Wealth Management LLC increased its holdings in shares of argenx by 3.4% in the fourth quarter. Dynasty Wealth Management LLC now owns 677 shares of the company's stock valued at $416,000 after purchasing an additional 22 shares during the last quarter. Finally, Choreo LLC boosted its holdings in argenx by 4.4% in the 4th quarter. Choreo LLC now owns 551 shares of the company's stock valued at $342,000 after purchasing an additional 23 shares during the last quarter. Institutional investors own 60.32% of the company's stock.

Wall Street Analysts Forecast Growth

ARGX has been the topic of several research reports. Guggenheim increased their price target on shares of argenx from $775.00 to $1,100.00 and gave the stock a "buy" rating in a research report on Monday, March 10th. Deutsche Bank Aktiengesellschaft raised argenx from a "sell" rating to a "hold" rating in a research report on Wednesday, March 12th. Wells Fargo & Company lifted their price target on argenx from $723.00 to $741.00 and gave the stock an "overweight" rating in a report on Friday, February 28th. HC Wainwright reissued a "buy" rating and set a $720.00 target price on shares of argenx in a research report on Tuesday, April 8th. Finally, JMP Securities raised their price objective on argenx from $606.00 to $696.00 and gave the stock a "market outperform" rating in a report on Tuesday, January 14th. Three research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $699.28.

argenx Stock Performance

Shares of ARGX traded up $6.36 during mid-day trading on Tuesday, hitting $627.33. The company's stock had a trading volume of 40,718 shares, compared to its average volume of 306,834. argenx SE has a one year low of $352.77 and a one year high of $678.21. The stock's 50-day moving average is $597.89 and its two-hundred day moving average is $609.60. The firm has a market capitalization of $38.30 billion, a PE ratio of -711.59 and a beta of 0.60.

argenx (NASDAQ:ARGX - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The business had revenue of $761.22 million during the quarter, compared to analysts' expectations of $678.52 million. Analysts expect that argenx SE will post 3.13 EPS for the current fiscal year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.